New pill shows promise for lung scarring disease
Disease control
Completed
This study tested a daily oral drug called TTI-101 in 100 people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and breathing problems. The main goal was to see if the drug is safe and tolerable over 12 weeks. Researchers also measured how the drug …
Phase: PHASE2 • Sponsor: Tvardi Therapeutics, Incorporated • Aim: Disease control
Last updated May 13, 2026 16:02 UTC